U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a bold plan to identify the cause of autism by September 2025. Speaking at a cabinet meeting with President Donald Trump, Kennedy declared a global research initiative involving hundreds of scientists to determine the source of rising autism rates, which reached 1 in 36 children by 2020, according to the CDC.
“We’ll know by September what has caused the autism epidemic and how to eliminate those exposures,” Kennedy said, hinting at environmental and artificial factors. The initiative is part of Trump’s broader “Make America Healthy Again” Commission, which is also reviewing rising childhood conditions like asthma and ADHD.
The autism community, however, responded with skepticism. Kristyn Roth of the Autism Society of America criticized the deadline and the framing of autism as an “epidemic,” warning it promotes fear and stigmatization. Experts caution that increased diagnoses are largely due to expanded diagnostic criteria and awareness, not an unknown epidemic.
Kennedy, known for promoting a disproven link between vaccines and autism, confirmed vaccines will be reviewed, along with potential environmental and lifestyle triggers. Meanwhile, a recent study has strengthened ties between prenatal diabetes and autism risk.
Controversy deepened after reports surfaced of David Geier—previously fined for unlicensed medical practices—being hired to investigate vaccine links. Lawmakers and advocacy groups fear the spread of misinformation under Kennedy’s leadership.
The National Institutes of Health and the CDC, both under Kennedy’s purview, are planning multimillion-dollar research efforts into autism causes, including vaccine-related studies. Critics argue the push may politicize science and mislead the public.
Despite widespread concern, Kennedy remains firm: “There will be no bigger news than finding the cause of autism.” Whether science can meet his deadline remains uncertain.


Federal Judge Declines to Immediately Halt Trump’s $300 Million White House Ballroom Project
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Pakistan’s Army Chief Faces Gaza Troop Dilemma Amid US Pressure
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Ukraine Claims First-Ever Underwater Drone Strike on Russian Missile Submarine
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
U.S. and Mexico Reach New Agreement to Tackle Tijuana River Sewage Crisis
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



